Law360, New York (October 27, 2010, 10:58 AM ET) -- Italy's antitrust watchdog has opened an investigation into whether a Pfizer Inc. unit has improperly extended patent protection for Xalatan to shield the glaucoma treatment from generic competition.
L’Autorita Garante della Concorrenza e del Mercato revealed the probe Tuesday with surprise inspections at the headquarters of Pfizer's Italian unit following a complaint from Ratiopharm, a major European generic-drug maker.
According to the complaint, Pfizer Italia SRL took a number of steps to keep generic versions of Xalatan off the Italian market, including fraudulently seeking an extension...
Pfizer Faces Italian Antitrust Probe Over Xalatan Patent
To view the full article, take a free trial now.
